Gamma Knife radiosurgery after radiation therapy as an adjunctive treatment for glioblastoma

Journal of Neuro-Oncology

Volumn 94, Issue 3, 2009, Pages 409-418

  Pouratian, Nader ^a   Crowley, R Webster ^a   Sherman, Jonathan H ^a   Jagannathan, Jay ^a   Sheehan, Jason P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Gamma Knife; Glioblastoma; Radiosurgery

Indexed keywords

ANTINEOPLASTIC AGENT; STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; GAMMA KNIFE RADIOSURGERY; GLIOBLASTOMA; HUMAN; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; STEREOTACTIC RADIOSURGERY;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; RADIOSURGERY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69249227523     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9873-9     Document Type: Article

References (40)

1. CBTRUS (2008) Statistical report: Primary brain tumors in the United States, 2000-2004. Central brain tumor registry of the United States. Accessed via http://www.cbtrus.org/reports//2007-2008/2007report.pdf. Accessed 01 Nov 2008
2. Chang JE, Khuntia D, Robins HI et al (2007) Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 5:894-902, 907-915
3. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/NEJMoa043330
4. Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 345:1008-1012. doi: 10.1016/ S0140-6736(95)90755-6
5. Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncology 5:79-88. doi: 10.1215/15228517-5-2-79
6. Walker MD, Strike TA, Sheline GE (1979) An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5:1725-1731
7. Silbergeld DL, Chicoine MR (1997) Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 86:525-531
8. Wallner KE, Galicich JH, Krol G et al (1989) Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405-1409
9. Hochberg FH, Pruitt A (1980) Assumptions in the radiotherapy of glioblastoma. Neurology 30:907-911
10. Sneed PK, Gutin PH, Larson DA et al (1994) Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 29:719-727
11. Kondziolka D, Flickinger JC, Bissonette DJ et al (1997) Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 41:776-783. doi: 10.1097/ 00006123-199710000-00004 (discussion 783-785)
12. Shrieve DC, Alexander E 3rd, Black PM et al (1999) Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: Prognostic factors and long-term outcome. J Neurosurg 90:72-77
13. Mahajan A, McCutcheon IE, Suki D et al (2005) Case-control study of stereotactic radiosurgery for recurrent glioblastoma multiforme. J Neurosurg 103:210-217
14. Nwokedi EC, DiBiase SJ, Jabbour S et al (2002) Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery 50:41-46. doi: 10.1097/00006123-200201000-00009 (discussion 46-47)
15. Combs SE, Widmer V, Thilmann C et al (2005) Stereotactic radiosurgery (SRS): Treatment option for recurrent glioblastoma multiforme (GBM). Cancer 104:2168-2173. doi: 10.1002/cncr.21429
16. Souhami L, Seiferheld W, Brachman D et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60:853-860. doi: 10.1016/ j.ijrobp.2004.04.011
17. Tsao MN, Mehta MP, Whelan TJ et al (2005) The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys 63:47-55. doi: 10.1016/j.ijrobp.2005.05.024
18. Scott CB, Scarantino C, Urtasun R et al (1998) Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40:51-55. doi: 10.1016/ S0360-3016(97)00485-9
19. Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704-710. doi: 10.1093/ jnci/85.9.704
20. Mirimanoff RO, Gorlia T, Mason W et al (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563-2569. doi: 10.1200/JCO.2005.04.5963
21. Gorlia T, van den Bent MJ, Hegi ME et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9:29-38. doi: 10.1016/S1470-2045(07)70384-4
22. Sarkaria JN, Mehta MP, Loeffler JS et al (1995) Radiosurgery in the initial management of malignant gliomas: Survival comparison with the RTOG recursive partitioning analysis. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 32:931-941. doi: 10.1016/ 0360-3016(94)00621-Q
23. Hohwieler Schloss M, Freidberg SR, Heatley GJ et al (1989) Glucocorticoid dependency as a prognostic factor in radiotherapy for cerebral gliomas. Acta Oncol 28:51-55. doi: 10.3109/02841868909111181
24. Kondziolka D, Somaza S, Martinez AJ et al (1997) Radioprotective effects of the 21-aminosteroid U-74389G for stereotactic radiosurgery. Neurosurgery 41:203-208. doi: 10.1097/00006123-199707000-00032
25. Kondziolka D, Mori Y, Martinez AJ et al (1999) Beneficial effects of the radioprotectant 21-aminosteroid U-74389G in a radiosurgery rat malignant glioma model. Int J Radiat Oncol Biol Phys 44:179-184. doi: 10.1016/ S0360-3016(98)00552-5
26. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578
27. Hau P, Baumgart U, Pfeifer K et al (2003) Salvage therapy in patients with glioblastoma: Is there any benefit? Cancer 98:2678-2686. doi: 10.1002/cncr.11845
28. Stummer W, Reulen HJ, Meinel T et al (2008) Extent of resection and survival in glioblastoma multiforme: Identification of and adjustment for bias. Neurosurgery 62:564-576 (discussion 564-576)
29. Keles GE, Lamborn KR, Chang SM et al (2004) Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 100:41-46
30. Hsieh PC, Chandler JP, Bhangoo S et al (2005) Adjuvant gamma knife stereotactic radiosurgery at the time of tumor progression potentially improves survival for patients with glioblastoma multiforme. Neurosurgery 57:684-692. doi: 10.1227/01.NEU.0000175550.96901.A3 (discussion 684-692)
31. Hall WA, Djalilian HR, Sperduto PW et al (1995) Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol 13:1642-1648
32. Loeffler JS, Alexander E 3rd, Shea WM et al (1992) Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 10:1379-1385
33. Shaw E, Scott C, Souhami L et al (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47:291-298. doi: 10.1016/S0360-3016(99)00507-6
34. Florell RC, Macdonald DR, Irish WD et al (1992) Selection bias, survival, and brachytherapy for glioma. J Neurosurg 76:179-183
35. Curran WJ Jr, Scott CB, Weinstein AS et al (1993) Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: A report of Radiation Therapy Oncology Group 83-02. J Clin Oncol 11:857-862
36. Irish WD, Macdonald DR, Cairncross JG (1997) Measuring bias in uncontrolled brain tumor trials - to randomize or not to randomize? Can J Neurol Sci 24:307-312
37. Lustig RA, Scott CB, Curran WJ (2004) Does stereotactic eligibility for the treatment of glioblastoma cause selection bias in randomized studies? Am J Clin Oncol 27:516-521. doi: 10.1097/ 01.coc.0000135641.82026.c4
38. Gomez-Rio M, Rodriguez-Fernandez A, Ramos-Font C et al (2008) Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence. Eur J Nucl Med Mol Imaging 35:966-975. doi: 10.1007/s00259-007-0661-5
39. Hu LS, Baxter LC, Smith KA et al (2009) Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: Direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 30:552-558
40. Zeng QS, Li CF, Zhang K et al (2007) Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J Neurooncol 84:63-69. doi: 10.1007/s11060-007-9341-3